Infliximab therapy intensification upon loss of response: Is there an optimal trough level?

07:00 EST 5th March 2019 | BioPortfolio

Summary of "Infliximab therapy intensification upon loss of response: Is there an optimal trough level?"

Loss of response (LOR) to infliximab occurs in ∼30% of IBD patients. At time of LOR, lower infliximab-trough-levels (TL), in the absence of anti-drug-antibodies (ATI), have been associated with the need for therapy escalation. Nevertheless, few studies have examined the outcome of infliximab-therapy intensification, based on different TL.


Journal Details

This article was published in the following journal.

Name: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562


DeepDyve research library

PubMed Articles [23666 Associated PubMed Articles listed on BioPortfolio]

Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis.

Infliximab is an effective salvage therapy in acute severe ulcerative colitis; however, the optimal dosing strategy is unknown. We performed a systematic review and meta-analysis to examine the impact...

Development of a C1q-immobilized (Cim) assay to measure total antibodies to infliximab and its clinical relevance in patients with inflammatory bowel disease.

Determination of antibodies to infliximab (ATI) is desirable for the management of patients with inflammatory bowel disease (IBD) who receive infliximab. Conventional ligand-binding ATI-assays detect ...

Combination Therapy with Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy-a Post-hoc analysis.

Among immunosuppressive- and biologic-naïve patients with moderate to severely active Crohn's disease (CD), a higher proportion of those treated with the combination of infliximab and azathioprine ac...

ZNF133 Is Associated with Infliximab Responsiveness in Patients with Inflammatory Bowel Diseases.

Infliximab has been widely prescribed for treating inflammatory bowel disease (IBD). However, the response rates to infliximab differ among patients. Therefore, we aimed to identify the genetic and cl...

Optimising infliximab induction dosing for patients with ulcerative colitis.

Therapeutic failure of infliximab therapy in patients with ulcerative colitis remains a challenge even two decades after its approval. Therapeutic drug monitoring (TDM) has shown value during maintena...

Clinical Trials [10711 Associated Clinical Trials listed on BioPortfolio]

Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy

To compare treatment outcome in patients with Crohn's disease with secondary loss of response to infliximab (i.e. initial good response follow by loss of response) treated according to cur...

Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)

Patients from an ongoing observational study (P05319) who have a limited (adequate but less than optimal) response to infliximab will be randomized to either increase the frequency of infl...

Comparison of the Performance of SB2-Infliximab With Originator Infliximab in the Measure of Serum Concentrations in Serum

The measurement of serum concentrations of infliximab (IFX)has now become a routine part of optimal use of that drug. Trough values are used in two situations: (a) reactively where there i...

Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator

The immunogenicity of anti-tumor necrosis factor alpha (anti-TNF) therapy in inflammatory bowel disease (IBD) is an important cause of loss of response to therapy that may lead to escalati...

Treatment With Infliximab in a Medical Setting (Study P05587)

This is an open-label, interventional study where a subset of patients will be randomized to one of two treatment-optimization strategies. Subjects with moderate to severe Crohn's disease...

Medical and Biotech [MESH] Definitions

A state of well-being in which performance is optimal, often as a result of physical conditioning which may be prescribed for disease therapy.

An induced response to threatening stimuli characterized by complete loss of muscle strength.

Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.

Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.

A chimeric monoclonal antibody to TNF ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE.

Quick Search


DeepDyve research library

Relevant Topic

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Searches Linking to this Article